Astrazeneca plc ADR (AZN) concluded trading on Wednesday at a closing price of $70.25, with 3.61 million shares of worth about $253.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -10.35% during that period and on January 29, 2025 the price saw a gain of about 0.95%. Currently the company’s common shares owned by public are about 3.10B shares, out of which, 3.10B shares are available for trading.
Stock saw a price change of 3.01% in past 5 days and over the past one month there was a price change of 5.61%. Year-to-date (YTD), AZN shares are showing a performance of 7.22% which increased to 4.69% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $60.47 but also hit the highest price of $87.68 during that period. The average intraday trading volume for Astrazeneca plc ADR shares is 6.24 million. The stock is currently trading 4.51% above its 20-day simple moving average (SMA20), while that difference is up 5.53% for SMA50 and it goes to -6.27% lower than SMA200.
Astrazeneca plc ADR (NASDAQ: AZN) currently have 3.10B outstanding shares and institutions hold larger chunk of about 15.82% of that.
The stock has a current market capitalization of $217.85B and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 33.76, while it has posted earnings per share of $2.08 in the same period. Its PEG reads 2.73 and has Quick Ratio of 0.71 while making debt-to-equity ratio of 0.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AZN, volatility over the week remained 1.07% while standing at 1.22% over the month.
Stock’s fiscal year EPS is expected to rise by 13.31% while it is estimated to increase by 12.63% in next year. EPS is likely to shrink at an annualized rate of 12.37% for next 5-years, compared to annual growth of 17.72% made by the stock over the past 5-years.
On September 13, 2024, Deutsche Bank Downgrade their recommendations, while on May 30, 2024, Goldman Initiated their ratings for the stock with a price target of $97. Stock get a Hold rating from Deutsche Bank on April 16, 2024.
